2017 Annual Report


Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam ultricies neque sit amet tortor malesuada tristique. Suspendisse cursus scelerisque lacus, sit amet mollis mi hendrerit non. Mauris at imperdiet libero. Vestibulum commodo ex lorem, ac tincidunt lectus pharetra vel. Vivamus ut lacus sed tortor commodo bibendum. Morbi ultrices elit ac purus egestas vestibulum. Nam consectetur malesuada ipsum, sit amet mattis lorem iaculis at.


Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam ultricies neque sit amet tortor malesuada tristique. Suspendisse cursus scelerisque lacus, sit amet mollis mi hendrerit non. Mauris at imperdiet libero. Vestibulum commodo ex lorem, ac tincidunt lectus pharetra vel. Vivamus ut lacus sed tortor commodo bibendum. Morbi ultrices elit ac purus egestas vestibulum. Nam consectetur malesuada ipsum, sit amet mattis lorem iaculis at.

Global Landscape

854+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies

Financings

Total 2017 Global Financings

Total Global Financing

$7.5 Billion

78.5%

Increase from 2016

100.0%010123456undefined
Gene & Gene-modified
Cell Therapy

$4.5 Billion

164%

Increase from 2016

100.0%0100.511.522.533.54undefined
Cell Therapy

$4 Billion

122%

Increase from 2016

100.0%0100.511.522.533.54undefined
Tissue Engineering

$446.1 Million

 5%

Decrease from 2016

100.0%01050100150200250300undefined

Total Global Financings by Type, by Year

165322442216183296317615888896471194837105323039781086132851913539IPOsFollow-OnsCorporate PartnershipsVenture CapitalPipesMergers & Acquisitions0200040006000800010000120001400016000201520162017

946

Clinical trials underway
worldwide by the end of Q3 2017

PH. 1

314

PH. 2

550

PH. 3

82

100.0%010102030405060708090undefined

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology: 2017

Gene & Gene-modified
Cell Therapy
100.0%01051015202530undefined
Cell Therapy
100.0%010510152025303540undefined
Tissue Engineering
100.0%01-0.500.511.522.533.544.555.5undefined

Clinical Trials by Indication: Q3 2017